Company profile

Aida Oncology company profile

Despite massive investment in oncology over the last 30 years, the efficacy of cancer treatments remains stubbornly low. Positive response rates of c.25% (i.e., only 1 in 4 patients) that receive a drug, will benefit from it are typical. New drugs are still being approved with response rates lower than this. Aida will transform the treatment of cancer by increasing the positive response rates to more than 50%. Aida can deliver this via our proprietary algorithmic approach to tumor transcriptome analysis, allowing us to predict a patient’s response to a drug. By predicting on multiple drugs (from one biopsy), we..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Founded
2021-01-01

Headquarters

Headquarters
Copenhagen, Capital Region, Denmark
Postal code
2200
Country code
DK
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
1
Total equity funding
$533.4K
Last funding
Pre Seed / $533.4K / 2023-03-01
Last equity funding
Pre Seed / $533.4K
Investors
1
Lead investors
1
Founders
3

Categories and groups

Founders and investors

Founders

Andy GardinerNeil GoldsmithPeter Buhl Jensen

Lead investors

BioInnovation Institute Venture Lab

Investors

BioInnovation Institute Venture Lab

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.